Table 5.
Tyrosine kinase inhibitors used alone or in combinatorial therapy in interventional clinical trials currently recruiting or not yet recruiting. Data acquired from the U.S. National library of medicine (http://clinicaltrials.gov, accessed on 16 January 2019).
| Tyrosine Kinase Inhibitor | Inhibited Tyrosine Kinases | Therapeutic Strategy/Objective | Cancer Type | Phase | Clinical Trial Reference |
|---|---|---|---|---|---|
| Sitravatinib (MGCD516) | c-Met, AXL, MER, VEGFR 1, PDGFR 2, DDR2, TRK 3, Eph 4 | Dosage and clinical activity of Sitravatinib | Advanced cancer | 1/1b | NCT02219711 |
| Sitravatinib with Nivolumab (Opdivo, anti-PD-1 5) | Renal cell cancer | 1/2 | NCT03015740 | ||
| Axitinib (AG-013736) | VEGFR1-3, c-KIT, PDGFR | Avelumab (anti-PD-1) with Axitinib | Non-small cell lung or urothelial cancer | 2 | NCT03472560 |
| Sandostatin LAR with Axitinib vs. with placebo | Neuroendocrine tumors | 2/3 | NCT01744249 | ||
| Cabozantinib | c-Met, VEGFR | Nivolumab (anti-PD-1) vs. Nivolumab with Cabozantinib | Renal cell carcinoma | 3 | NCT03793166 |
| Lenvatinib | VEGFR1-3 | Lenvatinib with Pembrolizumab (anti-PD-1) vs. Paclitaxel or Doxorubicin | Endometrial neoplasms | 3 | NCT03517449 |
1 VEGFR, Vascular endothelial growth factor receptor; 2 PDGFR, Platelet-derived growth factor receptor; 3 TRK, Tropomyosin receptor kinase; 4 Eph, Ephrin receptor; 5 PD-1, Programmed death receptor 1.